LENZ Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except for shares and par value)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $30,553 | $25,179 |
| Marketable securities | 166,750 | 267,168 |
| Accounts receivable, net | 913 | 329 |
| Inventory | 4,760 | 2,936 |
| Prepaid expenses and other current assets | 3,921 | 5,800 |
| Total current assets | 206,897 | 301,412 |
| Property and equipment, net | 640 | 1,189 |
| Operating lease right-of-use asset | 421 | 734 |
| Other assets | 1,791 | 2,541 |
| Total assets | $209,749 | $305,876 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,517 | $4,167 |
| Accrued liabilities | 12,233 | 17,020 |
| Total current liabilities | 17,750 | 21,187 |
| Operating lease liability, net | — | 350 |
| Total liabilities | 17,750 | 21,537 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' equity: | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock, par value of $0.00001 per share; 300,000,000 shares authorized; 31,420,583 and 31,344,782 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 524,571 | 511,237 |
| Accumulated deficit | (331,516) | (227,141) |
| Accumulated other comprehensive (loss) income | (1,057) | 242 |
| Total stockholders’ equity | 191,999 | 284,339 |
| Total liabilities and stockholders’ equity | $209,749 | $305,876 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.